About Us

Psychedelics as a movement can trace its roots well into past centuries or and multiple cultures. Psychedelics as an industry, however, is only just finding its feet. The Psychedelic Business Journal is here to provide a strategic context for the psychedelic industry with defined segments and quantative analysis worthy of its history and potential.

Pairing sales growth and investment tracking data with expert insight and analysis, PBJ is designed to help investors and innovators make sense of where the opportunities are now, and where they may be two years from now. We will also keep readers updated on the latest science news and follow the regulatory changes that could impact how that science comes to market, providing a roadmap to avoid the pitfalls common to emerging markets.

The goal is to stimulate the conversation and create a community that will help sustain a mental health revolution that the psychedelic movement has long sought to spark, but that will take a psychedelic industry to realize at scale.

The Psychedelic Business Summit convenes leaders across research, clinical delivery, regulation, and capital markets to shape the future of psychedelic therapeutics.
‍
As scientific progress accelerates and regulatory frameworks evolve, the industry faces a defining moment that demands discipline, coordination, and credible pathways to scale. The Summit bridges early-stage innovators with operating care providers, policymakers, legal experts, and investors to align research with real-world commercialization. By fostering dialogue across compounds, indications, and delivery models, it advances regulatory clarity, scalable infrastructure, and investable business frameworks.

Above all, the Summit seeks to galvanize this community around a shared mission: advancing human health and wellness while ensuring emerging alternatives are safe, affordable, and accessible to the broader population.